TY - JOUR
T1 - An LC-ESI-MS/MS method for determination of ondansetron in low-volume plasma and cerebrospinal fluid
T2 - Method development, validation, and clinical application
AU - Siemiątkowska, Anna
AU - Frey, Karen
AU - Gurba, Katharine N.
AU - Crock, Lara W.
AU - Haroutounian, Simon
AU - Kagan, Leonid
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/10/25
Y1 - 2023/10/25
N2 - Ondansetron is used in clinical settings as an antiemetic drug. Although the animal studies showed its potential effectiveness also in treating neuropathic pain, the results from humans are inconclusive. The lack of efficacy of ondansetron in a subset of patients might be due to the overexpression of P-glycoprotein, which could result in low concentrations of ondansetron in the central nervous system (CNS). A surrogate of the CNS exposure might be drug concentration in the cerebrospinal fluid (CSF), especially in humans, as assessing the drug disposition directly in the patient's brain would be challenging. The study aimed to develop a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine concentrations of ondansetron in human K3EDTA plasma and CSF. Ondansetron was extracted from biological matrices by liquid-liquid extraction. The quantification was performed on a Sciex QTRAP 6500+ mass spectrometer with labeled ondansetron as an internal standard. The calibration range was 0.25–350 ng/mL in plasma and 0.025–100 ng/mL in CSF; for both matrices, 25 µL of samples was required for the assays. The method was validated according to the FDA and EMA guidelines and showed acceptable results. A pilot study confirmed its suitability for clinical samples: after 4–16 mg of intravenous ondansetron, the determined concentrations in plasma were 1.22–235.90 ng/mL, while in CSF - 0.018–11.93 ng/mL. In conclusion, the developed method fulfilled all validation requirements and can be applied to pharmacokinetic studies assessing the CNS ondansetron exposure in humans. The method's advantages, such as a low volume of matrix and a wide calibration range, support its use in a study in which rich sampling and various drug doses are expected.
AB - Ondansetron is used in clinical settings as an antiemetic drug. Although the animal studies showed its potential effectiveness also in treating neuropathic pain, the results from humans are inconclusive. The lack of efficacy of ondansetron in a subset of patients might be due to the overexpression of P-glycoprotein, which could result in low concentrations of ondansetron in the central nervous system (CNS). A surrogate of the CNS exposure might be drug concentration in the cerebrospinal fluid (CSF), especially in humans, as assessing the drug disposition directly in the patient's brain would be challenging. The study aimed to develop a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine concentrations of ondansetron in human K3EDTA plasma and CSF. Ondansetron was extracted from biological matrices by liquid-liquid extraction. The quantification was performed on a Sciex QTRAP 6500+ mass spectrometer with labeled ondansetron as an internal standard. The calibration range was 0.25–350 ng/mL in plasma and 0.025–100 ng/mL in CSF; for both matrices, 25 µL of samples was required for the assays. The method was validated according to the FDA and EMA guidelines and showed acceptable results. A pilot study confirmed its suitability for clinical samples: after 4–16 mg of intravenous ondansetron, the determined concentrations in plasma were 1.22–235.90 ng/mL, while in CSF - 0.018–11.93 ng/mL. In conclusion, the developed method fulfilled all validation requirements and can be applied to pharmacokinetic studies assessing the CNS ondansetron exposure in humans. The method's advantages, such as a low volume of matrix and a wide calibration range, support its use in a study in which rich sampling and various drug doses are expected.
KW - 5-HT3 receptor antagonist
KW - Assay validation
KW - Blank matrices
KW - Carry-over
KW - Methods comparison
KW - P-glycoprotein
UR - http://www.scopus.com/inward/record.url?scp=85169896229&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2023.115625
DO - 10.1016/j.jpba.2023.115625
M3 - Article
C2 - 37549552
AN - SCOPUS:85169896229
SN - 0731-7085
VL - 235
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
M1 - 115625
ER -